A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1331-1341

  Boulenger, Jean Philippe ^a,d   Huusom, A K T ^b   Florea, I ^b   Baemadraskdal T ^b   Sarchiapone, M ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b H LUNDBECK A S   (Denmark)

^c CATHOLIC UNIVERSITY   (Italy)

^d Montpellier 1 University   (France)

Author keywords

Escitalopram; Long term; Paroxetine; Remission; Severely depressed patients

Indexed keywords

ESCITALOPRAM; PAROXETINE;

ADULT; AGED; ANALYSIS OF COVARIANCE; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SAFETY;

EID: 33746118434     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115513     Document Type: Article

References (36)

1. Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006;367:153-67
2. Montgomery SA, Lecrubier Y. Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam [European College of Neuropsychopharmacology]. Eur Neuropsychopharmacol 1999;9:259-64
3. Hirschfeld RMA. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999;60:326-35
4. Kruijshaar ME, Hoeymans N, Bijl RV, et al. Levels of disability in major depression: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord 2003;77:53-64
5. Bradvik L, Berglund M. Late mortality in severe depression. Acta Psychiatr Scand 2001;103:111-6
6. Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med 2000;30:117-25
7. Sonawalla SB, Fava M. Severe depression - is there a best approach? CNS drugs 2001;15:765-76
8. Beizer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 2004;10:296-306
9. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison of clomipramine [A controlled multicenter study]. Psychopharmacology 1986;90:131-8
10. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affec Disord 1990;18:289-99
11. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994;55:55-9
12. Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004;174:163-76
13. Murdoch D, Keam SJ. Escitalopram. A review of its use in the management of major depressive disorder. Drugs 2005;65:2379-404
14. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006;7:429-40
15. Gorman J, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002;7(Suppl 1):40-4
16. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7
17. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-55
18. Llorca P-M, Azorin J-M, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005;59:268-75
19. Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003;7:259-68
20. Moore N, Verdoux H, Fantinoe B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-7
21. Kennedy SH, Andersen HF, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder: a meta-analysis versus selective serotonin reuptake inhibitors and venlafaxine XR. J Psychiatry Neurosci 2006;31:122-31
22. Dunner D, Kumar R. Paroxetine: a review of clinical experience. Pharmacopsychiatry 1998;31:89-101
23. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992;7:91-4
24. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43
25. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBF) Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002;3:69-86
26. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-31
27. Boulenger JP. Residual symptoms of depression: clinical and theoretical implications. Eur Psychiatry 2004;19:209-13
28. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006 [in press]
29. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005;30:445-60
30. Thase, ME. Treatment of severe depression. J Clin Psychiatry 2000;61:17-25
31. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002;17(Suppl 1):S27-S32
32. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-5
33. Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005;39:145-50
34. Muller MJ, Szegedi A, Wetzel H, Benkert O. Moderate and severe depression. Gradations for the Montgomery-Åsberg Depression Rating Scale. J Affect Disord 2000;60:137-40
35. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Åsberg depression rating scale (MADRS). J Affect Disord 2003;77:255-60
36. Bech P, Tanghj P, Cialdella P, et al. Escitalopram dose response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004;7:283-90